The medical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s demonstrating significant potential in clinical trials for managing obesity. Unlike some existing weight loss solutions, retatrutide appears to deliver a significant substantial reduction in body mass and improve metabolic function,